Study patients received valsartan 80mg bid for 1-2 weeks. The PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator valsartan in HFpEF patients.
#PARAGON TRIAL RESULTS FULL#
2-4 Clinicians are eager to provide therapy to the large HFpEF population, and these therapies provide meaningful benefit on risk of HF hospitalization, an effect that will help offset. Full results of the trial will be presented at the ESC Congress 2019 in September.
Indeed …Īnd … Open Orphan hails positive results for flu trial, Poolbeg Pharma signs option to licence a vaccine for infectious disease, InnovaDerma signs JV to “accelerate and develop” premature ejaculation brand. The findings from the PARAGON trial 8 and the studies with SGLT2 inhibitors provide evidence for improvement of some clinical outcomes among patients with HFpEF. “A sceptic might suggest that such positivity is simply a sensible defence strategy,” the European bank said. Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC): Symptom burden and outcomes in patients with platinum. Read more 5 - BT Group talks up its business ahead of Drahi deadlineīerenberg, in a new note, repeated a ‘buy’ recommendation following upbeat conversations with key members of management team. The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. As a result, youll want to set your sights on naming options that are available.
#PARAGON TRIAL RESULTS GENERATOR#
Read more 4 - FTSE 100 posts strong reboundĪt the close, the UK's blue-chip index was up 109.96 points, or 1.5% to end Monday trading at 7,232.28. Hop out of the brand name generator and into your free 14-day trial. Stock traders (almost) every year cheer the so-called Santa Clause rally, but, so far it looks like Bitcoin, Ethereum and the other crypto markets look much more Grinchy.
Read more 3 - Forget a Santa rally, cryptos hit by Grinchey sell-off The risks associated with house price inflation, higher borrowing costs and the end of incentives for first-time buyers are largely priced in, though Persimmon has been singled out as most exposed to the end of ‘help-to-buy’. Read more 2 - Are Persimmon, Berkeley and the other builders a good bet?
#PARAGON TRIAL RESULTS DRIVERS#
Global energy transition and structural supply constraints are fundamental drivers for mining investment themes in 2022, highlights Alastair Ford, picking up research comments from Jefferies which is “most bullish on copper and aluminium – whilst tipping London-listed Anglo American, Glencore and Antofagasta in note. 1 - Copper and energy metals tipped to top mining in 2022